BRANFORD, Conn., Dec. 8, 2021 /PRNewswire/ -- IsoPlexis
(NASDAQ: ISO), the leader in functional single cell
proteomics, today announced that new data generated on its
IsoLight® platform will be presented at the 63rd annual
American Society of Hematology (ASH) conference, taking place
December 11-13 at the Georgia World
Congress Center in Atlanta,
Georgia.
At ASH, IsoPlexis' presented data will outline how to
leverage unique powerful single-cell subsets of highly functional
"superhero" cells, critical to driving longer term response in cell
and immune therapies via functional proteins. The presentation will
highlight how to fully leverage these superhero cells for
optimization of CAR-T manufacturing, as well as clinical
combination immunotherapies for hematologic malignancies and
functional biomarkers of potency, durability, and survival.
The presentation, titled "Single-Cell Functional Biomarkers
of Potency, Durability, and Survival in Cell Therapy Optimization
and Combination Immunotherapies for Hematologic
Diseases," will be given on Saturday, December
11 from 1:30 p.m. - 1:45 p.m. eastern time. The
presentation will be located in Theater 5 of Exhibit Hall –
Building B at the Georgia World Congress Center.
Additionally, the following poster presentations from
Stanford University, Medical College of Wisconsin, and Atara
Biotherapeutics will also highlight novel applications in acute
graft-versus-host disease (aGvHD), bispecific CAR-T cells, and
off-the-shelf allogenic T-cell therapies, respectively:
- P#1684: Combinatorial Cytokine Secretion Signature of
Donor-Derived T Cells Infused with the Graft: A New Potential
Biomarker of Acute Graft-Versus-Host Disease in Aβt-Cell/CD19
B-Cell Depleted Hematopoietic Stem Cell Transplant Recipients
- P#1728: Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and
IL-15 Have Greater Polyfunctionality and Polyfunctional Strength
Than CAR T-Cells Expanded in IL-2
- P#2809: Comprehensive Activation Profiling of the Tabelecleucel
Library, and Off-the-Shelf, Allogeneic EBV-Specific T-Cell
Therapy
About IsoPlexis
IsoPlexis is leading a new era of
functional proteomics. By identifying our most proteomically active
single cells (or "superhero cells") for the first time, IsoPlexis
enables researchers to connect more directly to in vivo biology and
develop more precise and personalized therapies. IsoPlexis has been
named Top Innovation or Design by The Scientist Magazine, Fierce,
BIG Innovation, Red Dot and multiple others. The IsoPlexis platform
is used globally by researchers, including those at the top 15
global pharmaceutical companies and at the majority of leading U.S.
comprehensive cancer centers.
Cautionary Note Regarding Forward Looking
Statements
Certain statements in this press release are
forward-looking statements that are subject to risks and
uncertainties that could cause results to be materially different
than expectations. Such statements can be identified by the use of
words such as "will". Important factors that could cause
actual results to differ materially include: the rate of adoption
of the Company's technology by its customers and potential
customers as well as the risk factors set forth in the Risk Factors
section of the Company's prospectus filed with the SEC. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, IsoPlexis disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
Related Links
www.isoplexis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isoplexis-to-present-isolight-single-cell-proteomics-data-at-ash-2021-conference-301439964.html
SOURCE IsoPlexis